Skip to main content
Fig. 4 | Respiratory Research

Fig. 4

From: Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies

Fig. 4

Lung function endpoints over time. Change from baseline in morning pre-dose trough FEV1 (a) and peak change from baseline in FEV1 within 2 h post-dose (b) (pooled ITT population). Data are least squares mean ± standard error. FEV1, forced expiratory volume in 1 s; FF, formoterol fumarate; GFF, glycopyrrolate/formoterol fumarate; GP, glycopyrrolate; ITT, intent-to-treat; LSM, least squares mean; MDI, metered dose inhaler

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us